Table III.
Specific recognition of HLA-A2+ MART1+ tumor cells by Jurkat 76/CD8αβ reconstituted with A2/MART1 TCRs
| TRBV27 chain
|
||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stimulator cells | HLA-A2 | MART1 | Cl.413 | Cl.523 | Cl.788 | Cl.1086 | Cl.758 | Cl.1593 | Cl.1574 | Cl.1599 | Cl.1606 | Cl.830 | Cl.794 | DMF5 |
| A375 | + | − | <10 | <10 | <10 | <10 | <10 | <10 | <10 | <10 | <10 | <10 | <10 | <10 |
| A375/MART1 | + | + | <10 | <10 | 21 (6) | 20 (5) | 45 (7) | 98 (8) | 55 (9) | 170 (3) | 94 (10) | 153 (8) | 197 (10) | 33 (3) |
| Malme-3M/siControl | + | + | <10 | <10 | 18 (5) | 19 (8) | 64 (6) | 73 (15) | 60 (11) | 143 (18) | 76 (10) | 99 (8) | 151 (15) | 39 (5) |
| Malme-3M/siMART1 | + | Low | <10 | <10 | 14 (5) | 14 (6) | 50 (6) | 54 (5) | 45 (9) | 99 (10) | 48 (4) | 75 (9) | 113 (11) | 27 (5) |
| SK-MEL-28 | − | + | <10 | <10 | <10 | <10 | <10 | <10 | <10 | <10 | <10 | <10 | <10 | <10 |
| SK-MEL-28/A2 | + | + | <10 | <10 | 34 (6) | 31 (4) | 67 (9) | 101 (14) | 81 (4) | 128 (14) | 70 (6) | 115 (10) | 147 (10) | 40 (6) |
| SK-MEL-37 | + | − | <10 | <10 | <10 | <10 | <10 | <10 | <10 | <10 | <10 | <10 | <10 | <10 |
| K562 | − | − | <10 | <10 | <10 | <10 | <10 | <10 | <10 | <10 | <10 | <10 | <10 | <10 |
Tumor cell recognition was assessed using various target cells, which did or did not express HLA-A2 and/or MART1, as stimulator cells in IL-2 ELISPOT assays. A half million Jurkat 76/CD8αβ cells, which were individually transduced with eleven distinct clonotypic TRBV27 TCRβ chains along with SIG35α or with DMF5αβ chains, were used as responder cells. Mean values of SFUs in triplicate samples are shown. SDs of triplicates are shown in parentheses.